Check-Cap Ltd. (NASDAQ: CHEK)

not many shares outstanding and trading at cash level plus first sales of their unique product c-scan in israel and europe expected this year ...huge upside here

strong buy aggressive

CHEK = MC $17 Million / Cash $18 Million / Shares Out 8.2 Million / ultra Low Float stock with MASSIVE upside potential . $20++ stock trading at ridiculous $2 .Super Strong Buy before stock gets discovered .GL


Colorectal Cancer Screening Pill to Be in US Pilot Study
https://www.mddionline.com/colorectal-cancer-screening-pill-be-us-pilot-study

New Presentation
http://ir.check-cap.com/download/CHECK+Corp+Presentation_January+2019.pdf


Check-Cap: This Overlooked Medical Device Company Is Extremely Undervalued

As a result of the much more established market and reimbursement paradigm for capsule endoscopy, in conjunction with C-Scan’s unique ability to circumvent the bowel preparation requirement and detect precancerous polyps, it is conceivable that Check-Cap could scale more than twice as quickly as Given Imaging did since it launched its first product. This implies potential sales for Check-Cap of more than $60M in 2020. Check-Cap believes that the global market opportunity for C-Scan in the US is $5.4B annually (See slide 10 in this presentation), comprised of a global population at age 50 and above of 710 million, an average procedure cost of $600, and a screening frequency of once every 10 years. Hence, $60M of sales contemplates only minimal penetration relative to the aggregate market opportunity. To demonstrate the potential revenue ramp of C-Scan, investors could also study the sales trajectory of Exact Sciences’ (NASDAQ:EXAS) Cologuard. Cologuard generated $26.5M in sales during the first four quarters since the product launched, and within 8 quarters, it exceeded a $100M annualized run-rate.

In my valuation, I was conservative and used only $50M of sales that are only reached in 2022. I used an EV/Sales multiple range of between 5 to 8 (given that the company will still be growing extremely fast). I then conservatively assumed that on top of all warrants being exercised there would be another 100% dilution, so a total of 17M shares. That leads me to a price target in the range of $15.8 and $24.6 at 2022, or 4.5X to 7X current prices. I then assign a 50% chance of success which brings me to a probability weighted price target of $8 to $12.3 or an IRR of 18% to 29%.

However, if you are optimistic and believe the $60M sales in 2020, then $100M of sales is plausible by 2022, and using an 8X multiple, this could potentially be a $800M EV by 2022 or ~$50/share using 15M shares (assuming 75% dilution on top of all warrants being exercised). Obviously, this is pretty much a best case scenario.

CHEK = MC $17 Million / Cash $18 Million / Shares Out 8.2 Million / ultra Low Float stock with MASSIVE upside potential . $20++ stock trading at ridiculous $2 .Super Strong Buy before stock gets discovered .GL


Colorectal Cancer Screening Pill to Be in US Pilot Study
https://www.mddionline.com/colorectal-cancer-screening-pill-be-us-pilot-study

New Presentation
http://ir.check-cap.com/download/CHECK+Corp+Presentation_January+2019.pdf


Check-Cap: This Overlooked Medical Device Company Is Extremely Undervalued

As a result of the much more established market and reimbursement paradigm for capsule endoscopy, in conjunction with C-Scan’s unique ability to circumvent the bowel preparation requirement and detect precancerous polyps, it is conceivable that Check-Cap could scale more than twice as quickly as Given Imaging did since it launched its first product. This implies potential sales for Check-Cap of more than $60M in 2020. Check-Cap believes that the global market opportunity for C-Scan in the US is $5.4B annually (See slide 10 in this presentation), comprised of a global population at age 50 and above of 710 million, an average procedure cost of $600, and a screening frequency of once every 10 years. Hence, $60M of sales contemplates only minimal penetration relative to the aggregate market opportunity. To demonstrate the potential revenue ramp of C-Scan, investors could also study the sales trajectory of Exact Sciences’ (NASDAQ:EXAS) Cologuard. Cologuard generated $26.5M in sales during the first four quarters since the product launched, and within 8 quarters, it exceeded a $100M annualized run-rate.

In my valuation, I was conservative and used only $50M of sales that are only reached in 2022. I used an EV/Sales multiple range of between 5 to 8 (given that the company will still be growing extremely fast). I then conservatively assumed that on top of all warrants being exercised there would be another 100% dilution, so a total of 17M shares. That leads me to a price target in the range of $15.8 and $24.6 at 2022, or 4.5X to 7X current prices. I then assign a 50% chance of success which brings me to a probability weighted price target of $8 to $12.3 or an IRR of 18% to 29%.

However, if you are optimistic and believe the $60M sales in 2020, then $100M of sales is plausible by 2022, and using an 8X multiple, this could potentially be a $800M EV by 2022 or ~$50/share using 15M shares (assuming 75% dilution on top of all warrants being exercised). Obviously, this is pretty much a best case scenario.

cash burn significantly reduced after failed trial in last quarter , they have cash untill end Q1 to mid 2020 according to ceo

NDA accepted by FDA
https://ih.advfn.com/stock-market/NASDAQ/clearside-biomedical-inc-CLSD/stock-news/79305004/clearside-biomedical-receives-notification-of-fda

Great NEws out

cheapest biotech out there at this time

Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma..February 19, 2019
https://globenewswire.com/news-release/2019/02/19/1734213/0/en/Seelos-Therapeutics-Completes-Acquisition-of-Trehalose-from-Bioblast-Pharma.html?culture=en-us

The good news start to come in ..this is a minimum $15++ stock trading at laughable $3.80

someone missed the boat and talking garbage will not change that muahahaha

and super low valuation

atrractive pipeline

will do some dd but looks great so far

cheap stock

NDA acceptance coming within days likely within 2 weeks , if we get priority review then FDA decision will be in 1H 2019 .

rallyyyyyyyyyyy

CLSD rallllyyyyyyyyyy again and still trading under cash

CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED low float Stock.GL

"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

MONSTER BREAKOUT COMING ...TGT $5 before FDA decision

rallyyyyyyyyyyyyyyy

CLSD rallllyyyyyyyyyy again and still trading under cash

CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED low float Stock.GL

"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

CLSD rallllyyyyyyyyyy again and still trading under cash

CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED low float Stock.GL

"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

up in pre mkt again ..$2+ coming NDA acceptance imminent

NDA acceptance coming any day now = $2.50 soon

CLSD skyrocketingggggg and still trading massive below cash



CLSD = Market cap $43 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED low float Stock.GL

"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."

insert-text-here

still trading wayy under cash balance , still amega opportuity here ahead of FDA approval

CLSD breakouts ..and still trading way below cash

CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash

https://static.seekingalpha.com/uploads/sa_presentations/253/37253/slides/45.jpg?1547230362

"If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024."

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

CLSD RALLYYYYYY ...and still trading wayyyy below cash

CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash.

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.

RALLYYYYYYYYYYYYYYYY $5 coming

Major breakout to start anytime now ..NDA acceptance news imminent

any dip here is a mega buying opportunity trading under cash and close to FDA decision

CLSD close to big leg up and still trading wayy below cash

M

CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance within 8 days & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil.UNDISCOVERED Stock trading almost 40% below Cash.

http://www.biotuesdays.com/briefs/2018/12/20/clearside-biomedical-submits-nda-for-xipere-in-macular-edema-associated-with-uveitis

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.

breakout coming

Nice volume today next leg up imminent

still trading significantly below cash ...She is on the move gain guys

Clearside Biomedical, Inc. (CLSD): Outperform Candidate With 330.88% Upside Potential

Clearside Biomedical, Inc. is maintained at an average outperform rating by 8 stock analysts, and there are at least 2.8% of shares outstanding that are currently legally short sold. The shares went up by 15.25% in value last month. Year-to-date it jumped 27.1%. Analysts are turning out to be more optimistic than before, with 5 of analysts who cover Clearside Biomedical, Inc. (NASDAQ:CLSD) advice adding it to buy candidate list. Wall Street experts also assign a $5.86 price target on Clearside Biomedical, Inc., pointing towards a 330.88% rally from current levels. The stock is trading for about -91.13% less than its 52-week high.

https://www.postanalyst.com/2019/02/11/sizzling-technical-charts-clearside-biomedical-inc-clsd-golden-entertainment-inc-gden/

$2 coming closer will hit $5 longBEFORE FDA decision easily

up in pre market could be another good day for CLSD

LOL well good luck you will need it but please dont cry when you lose everything lol

US sales ok what about the rest of the World EMA filing for the approval in Europe also expected this year . What a about potential Upfront payments from potential Partners which could be higher than the entire valuation of CLSD (Market cap $42 Million) .Looks like your math is not good but i know what your intention is hehe .

Again if you want cheap shares then i wouldnt wait to long hehe. CLSD is trading way below Cash and FDA approval could come by mid year with priority review but we could have a very nice run up ahead of the FDA decision thats what underpriced biotechs usually do.Oh and there is nothing personal in my previous post .